# The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer

> **NCT04179968** · PHASE2 · COMPLETED · sponsor: **Dana Mathews** · enrollment: 20 (actual)

## Conditions studied

- Prostate Cancer
- Prostate Cancer Metastatic

## Interventions

- **DRUG:** 68Ga PSMA-11 injection
- **PROCEDURE:** Positron Emission Tomography/Computed Tomography

## Key facts

- **NCT ID:** NCT04179968
- **Lead sponsor:** Dana Mathews
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-27
- **Primary completion:** 2021-09-09
- **Final completion:** 2022-07-15
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04179968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04179968, "The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04179968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*